Transfusion of convalescent plasma promises mortality benefits in immunocompromised COVID-19 patients

Mayo Clinic: A recent Original Investigation for Infectious Diseases published in JAMA Network Open has mentioned that convalescent plasma is tied to mortality benefits to hospitalised patients with primary or secondary immunosuppression and COVID-19.

Immunocompromised patients have a higher risk for morbidity and mortality associated with COVID-19. They mount antibody responses less frequently to vaccines. To treat COVID-19, neutralizing anti-spike monoclonal-antibody treatment has been used, but evolutions of SARS-CoV-2 have been related to monoclonal antibody-resistant SARS-CoV-2 variants and greater virulence and transmissibility of SARS-CoV-2. COVID-19 convalescent plasma has increased therapeutically based on the presumption that plasma contains antibodies to SARS-CoV-2, which are potentially therapeutic and can be transferred passively to the recipient.

What is the pooled evidence in this context?

Investigating further, a researchers team did a study to assess the growing reports of clinical experiences of COVID-19 immunocompromised patients treated with COVID-19 convalescent plasma transfusion. The lead researcher was Jonathon W.Senefeld, PhD. The study points are:

• The researchers selected relevant RCTs, matched cohort studies, and case reports or series